西洋参多糖对BABL/C小鼠肝癌肿瘤的抑制效果

doi:10.3969/j.issn.1002-3070.2012.06.002

Abstract

Abstract: Objective For the research suppression glucogalactan from the roots of Panax quinquefolium to hepatocellular carcinoma,we study the treatment effect of glucogalactan from Panax Quinquefolium(PPQ)to hepatocellular carcinoma.Methods We established BABL/C mouse model of hepatocellular carcinoma;used PPQ interference mouse hepatocellular carcinoma development;observed the variation of mouse hepatocellular carcinoma and spleen and estimated effect of anti-hepatocellular carcinoma and PPQ immunoregulation.Results With the increasing of PPQ dosage,mice tumor weight decrease obviously,and tumor inhibitory rate increase obviously(P＜0.05).Mice immunoregulatory effect is remarkable.Conclusion So,PPQ to the tumor inhibition is obvious.It may provide a new way for tumor immunotherapy.

Key words: Panax quinquefolium L, Hepatocellular carcinoma, H22 cell, Immunoregulatory effects

CLC Number:

R735.7

ZHU Wenjing,YANG Xiuhua,GUO Cunli,AN Tingting,ZHANG Jiuwei. Immunosuppressive effect of a Glucogalactan from Panax quinquefolium L.on hepatocellular carcinoma model of BABL/C mice[J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(6): 486-489.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.3969/j.issn.1002-3070.2012.06.002

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2012/V26/I6/486

[1]	ZHU Lei, HAO Dandan. Research progress on non-coding RNAs in the regulation of ferroptosis mediated sorafenib resistance in hepatocellular carcinoma [J]. Journal of Practical Oncology, 2025, 39(3): 256-261.
[2]	ZHANG Kangjun, FANG Taishi, CEN Fulan, YAN Xu, CHEN Qijun, MA Nan. circ_0008043 promotes glycolysis of hepatocellular carcinoma and the development of hepatocellular carcinoma through miR-198/SLC2A1 axis [J]. Journal of Practical Oncology, 2024, 38(6): 388-401.
[3]	GUAN Yongyu, NIE Hao, ZHANG Chong. Research progress of hepatocellular carcinoma mouse models [J]. Journal of Practical Oncology, 2024, 38(5): 342-348.
[4]	WU Dongyang, CAI Qingshan, LIU Dong, ZUO Ganggang, LI Shudong, LIU Liyou, ZHENG Jianxing. The effects and mechanism of long non-coding RNA CASC15 on proliferation,invasion and migration of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2024, 38(1): 18-29.
[5]	PANG Wu, CHEN Lijiang, ZHU Yu, WU Yakun, ZHANG Wei. The expression of serum miRNA-24 and miRNA-509 in patients with hepatocellular carcinoma and their correlation with prognosis [J]. Journal of Practical Oncology, 2023, 37(5): 411-415.
[6]	CUI Yongkang, YU Chengping, XU Haozhi, MA Xinyu, MA Yong, LI Linqiang. Effects of nutritional risk index in predicting postoperative complications and prognosis of patients with resectable hepatocellular carcinoma [J]. Journal of Practical Oncology, 2023, 37(3): 243-251.
[7]	YIN Dingwei, JING Jie. Research progress on the role of Gut microbiota in hepatocellular carcinoma and its therapeutic application [J]. Journal of Practical Oncology, 2023, 37(3): 281-286.
[8]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[9]	LIU Jia, YANG Daokun, WANG Yanping, CHEN Baoxin, WANG Xinwei, SHEN Jiao. Research status of biomarkers related to the efficacy of PD-1 inhibitors in the treatment of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(4): 374-380.
[10]	LIU Jiaming, CUI Yifeng, LU Zhaoyang. Aqueous Huaier extract inhibits the proliferation and metastasis of hepatocellular carcinoma by regulating the Akt signaling pathway through mitochondrial transcription factor A [J]. Journal of Practical Oncology, 2022, 36(3): 203-207.
[11]	PANG Chunhua, LI Fanrong, TANG Rubing, QIN Lei, ZHAO Xinhua, TANG Juan, YOU Xuemei. Association between preoperative fatigue status and postoperative quality of life in patients with advanced hepatocellular carcinoma:a prospective cohort study [J]. Journal of Practical Oncology, 2022, 36(2): 127-132.
[12]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[13]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[14]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[15]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.

Immunosuppressive effect of a Glucogalactan from Panax quinquefolium L.on hepatocellular carcinoma model of BABL/C mice

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments